CELEX: 62020TA0542
Language: en
Date: 2021-11-10 00:00:00
Title: Case T-542/20: Judgment of the General Court of 10 November 2021 — Stada Arzneimittel v EUIPO — Pfizer (RUXIMBLIS) (EU trade mark — Opposition proceedings — Application for the EU word mark RUXIMBLIS — Earlier EU word mark RUXIMERA — Relative ground for refusal — Likelihood of confusion — Similarity of the signs — Article 8(1)(b) of Regulation (EU) 2017/1001)

3.1.2022   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 2/33
            
         
      Judgment of the General Court of 10 November 2021 — Stada Arzneimittel v EUIPO — Pfizer (RUXIMBLIS)
      (Case T-542/20) (1)
      
      (EU trade mark - Opposition proceedings - Application for the EU word mark RUXIMBLIS - Earlier EU word mark RUXIMERA - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation (EU) 2017/1001)
      (2022/C 2/44)
      Language of the case: English
      
         Parties
      
      
         Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)
      
         Defendant: European Union Intellectual Property Office (represented by: T. Frydendahl, A. Folliard-Monguiral and D. Gája, acting as Agents)
      
         Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Pfizer Inc. (New York, New York, United States) (represented by: V. von Bomhard, J. Fuhrmann and P.-F. Karamolegkou, lawyers)
      
         Re:
      
      Action brought against the decision of the Fourth Board of Appeal of EUIPO of 16 June 2020 (Case R 1877/2019-4), relating to opposition proceedings between Pfizer and Stada Arzneimittel.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the action;
               
            
                  2.
               
               
                  Orders Stada Arzneimittel AG to pay the costs.
               
            
         (1)  OJ C 339, 12.10.2020.